BackXenetic Biosciences Overview

Xenetic Biosciences Total Current Liabilities

Xenetic Biosciences's total current liabilities is $960K.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$958239.00
43.46% YoYΔ $290312.00 vs prior year quarter

Peer average

Loading

Xenetic Biosciences Total Current Liabilities History

Loading

Xenetic Biosciences vs. peers: Total Current Liabilities Comparison

Loading

Xenetic Biosciences Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Xenetic Biosciences (XBIO) FAQ

The latest total current liabilities for XBIO is $960K as of March 2026. That compares with $670K in the prior-year period — up 43.5% year over year. Investors often review this figure alongside Xenetic Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, XBIO's total current liabilities moved from $670K to $960K — a 43.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Xenetic Biosciences's operating scale or balance-sheet position.

A total current liabilities figure of $960K for XBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting XBIO's total current liabilities ($960K), review year-over-year change from $670K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Xenetic Biosciences's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.